Related references
Note: Only part of the references are listed.Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy
Alejandro Berlin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015
Brandon A. Mahal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
Seth A. Rosenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone
Rana R. McKay et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.
Felix Y. Feng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
LBA-12 CALGB 90203 (ALLIANCE): RADICAL PROSTATECTOMY WITH OR WITHOUT NEOADJUVANT CHEMOHORMONAL THERAPY IN MEN WITH CLINICALLY LOCALIZED, HIGH RISK PROSTATE CANCER
James A. Eastham* et al.
JOURNAL OF UROLOGY (2019)
Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers
Debasish Sundi et al.
CANCER (2019)
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer
Anis A. Humid et al.
EUROPEAN UROLOGY (2019)
The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer
Matthew R. Cooperberg et al.
EUROPEAN UROLOGY (2018)
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial
Abdenour Nabid et al.
EUROPEAN UROLOGY (2018)
Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features
R. Jeffrey Karnes et al.
EUROPEAN UROLOGY (2018)
Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer
Daniel E. Spratt et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy Defining a Favorable Intermediate-Risk Group
Hiten D. Patel et al.
JAMA ONCOLOGY (2018)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2018)
Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens
Paul L. Nguyen et al.
EUROPEAN UROLOGY (2017)
Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease
Daniel E. Spratt et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men
Ashley E. Ross et al.
EUROPEAN UROLOGY (2016)
Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens
Beatrice S. Knudsen et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk
Eric A. Klein et al.
UROLOGY (2016)
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer
Tamara L. Lotan et al.
EUROPEAN UROLOGY FOCUS (2016)
Trends in Management for Patients With Localized Prostate Cancer, 1990-2013
Matthew R. Cooperberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Who dies from prostate cancer?
A. Patrikidou et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2014)
Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy
Nicholas Erho et al.
PLOS ONE (2013)
Contemporary Evaluation of the National Comprehensive Cancer Network Prostate Cancer Risk Classification System
Adam C. Reese et al.
UROLOGY (2012)
Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy
Ofer Yossepowitch et al.
EUROPEAN UROLOGY (2008)
Share Paper
